Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $2,127 | 60 | 99.8% |
| Education | $3.26 | 1 | 0.2% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Horizon Therapeutics plc | $278.17 | 7 | $0 (2023) |
| Mallinckrodt Enterprises LLC | $244.50 | 2 | $0 (2019) |
| GlaxoSmithKline, LLC. | $242.05 | 14 | $0 (2023) |
| Fresenius USA Marketing, Inc. | $225.00 | 4 | $0 (2020) |
| AstraZeneca Pharmaceuticals LP | $223.90 | 3 | $0 (2020) |
| Amgen Inc. | $189.14 | 10 | $0 (2024) |
| Otsuka America Pharmaceutical, Inc. | $139.52 | 3 | $0 (2019) |
| Keryx Biopharmaceuticals, Inc. | $136.34 | 2 | $0 (2018) |
| OPKO Pharmaceuticals, LLC | $105.45 | 3 | $0 (2022) |
| AbbVie, Inc. | $93.47 | 1 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $247.20 | 12 | Amgen Inc. ($173.08) |
| 2023 | $103.04 | 4 | Horizon Therapeutics plc ($80.82) |
| 2022 | $232.67 | 11 | GlaxoSmithKline, LLC. ($77.08) |
| 2021 | $153.16 | 9 | GlaxoSmithKline, LLC. ($123.18) |
| 2020 | $208.19 | 3 | AstraZeneca Pharmaceuticals LP ($95.86) |
| 2019 | $667.08 | 12 | Mallinckrodt Enterprises LLC ($244.50) |
| 2018 | $518.54 | 10 | Keryx Biopharmaceuticals, Inc. ($136.34) |
All Payment Transactions
61 individual payment records from CMS Open Payments — Page 1 of 3
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 09/05/2024 | Amgen Inc. | KRYSTEXXA (Biological) | Food and Beverage | In-kind items and services | $17.98 | General |
| Category: Inflammation/Rare Disease | ||||||
| 08/29/2024 | Amgen Inc. | KRYSTEXXA (Biological) | Food and Beverage | In-kind items and services | $20.38 | General |
| Category: Inflammation/Rare Disease | ||||||
| 08/19/2024 | Amgen Inc. | KRYSTEXXA (Biological) | Food and Beverage | In-kind items and services | $22.96 | General |
| Category: Inflammation/Rare Disease | ||||||
| 08/14/2024 | Amgen Inc. | KRYSTEXXA (Biological) | Food and Beverage | In-kind items and services | $24.39 | General |
| Category: Inflammation/Rare Disease | ||||||
| 08/02/2024 | Amgen Inc. | KRYSTEXXA (Biological) | Food and Beverage | In-kind items and services | $2.79 | General |
| Category: Inflammation/Rare Disease | ||||||
| 07/16/2024 | Amgen Inc. | KRYSTEXXA (Biological) | Food and Beverage | In-kind items and services | $25.56 | General |
| Category: Inflammation/Rare Disease | ||||||
| 06/11/2024 | Amgen Inc. | KRYSTEXXA (Biological) | Food and Beverage | In-kind items and services | $19.08 | General |
| Category: Inflammation/Rare Disease | ||||||
| 05/28/2024 | Novartis Pharmaceuticals Corporation | — | Food and Beverage | In-kind items and services | $20.25 | General |
| 05/21/2024 | Amgen Inc. | KRYSTEXXA (Biological) | Food and Beverage | In-kind items and services | $19.97 | General |
| Category: Inflammation/Rare Disease | ||||||
| 05/06/2024 | Amgen Inc. | KRYSTEXXA (Biological) | Food and Beverage | In-kind items and services | $19.97 | General |
| Category: Inflammation/Rare Disease | ||||||
| 04/12/2024 | Aurinia Pharma U.S., Inc. | LUPKYNIS (Drug) | Food and Beverage | In-kind items and services | $24.39 | General |
| Category: LUPUS NEPHRITIS | ||||||
| 03/26/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $29.48 | General |
| Category: DIABETES | ||||||
| 11/14/2023 | Horizon Therapeutics plc | KRYSTEXXA (Biological) | Food and Beverage | In-kind items and services | $24.64 | General |
| Category: KRYSTEXXA | ||||||
| 09/29/2023 | Horizon Therapeutics plc | KRYSTEXXA (Biological) | Food and Beverage | In-kind items and services | $29.35 | General |
| Category: KRYSTEXXA | ||||||
| 08/31/2023 | Horizon Therapeutics plc | KRYSTEXXA (Biological) | Food and Beverage | In-kind items and services | $26.83 | General |
| Category: KRYSTEXXA | ||||||
| 08/02/2023 | GlaxoSmithKline, LLC. | BENLYSTA (Biological) | Food and Beverage | In-kind items and services | $22.22 | General |
| Category: IMMUNOLOGY | ||||||
| 08/22/2022 | Horizon Therapeutics plc | KRYSTEXXA (Biological) | Food and Beverage | In-kind items and services | $26.94 | General |
| Category: KRYSTEXXA | ||||||
| 07/26/2022 | GlaxoSmithKline, LLC. | BENLYSTA (Biological) | Food and Beverage | In-kind items and services | $14.05 | General |
| Category: IMMUNOLOGY | ||||||
| 05/31/2022 | GlaxoSmithKline, LLC. | BENLYSTA (Biological) | Food and Beverage | In-kind items and services | $30.98 | General |
| Category: IMMUNOLOGY | ||||||
| 04/27/2022 | Bayer HealthCare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $17.79 | General |
| Category: Cardio-renal | ||||||
| 04/21/2022 | GlaxoSmithKline, LLC. | BENLYSTA (Biological) | Food and Beverage | In-kind items and services | $17.42 | General |
| Category: IMMUNOLOGY | ||||||
| 02/22/2022 | OPKO Pharmaceuticals, LLC | RAYALDEE (Drug) | Food and Beverage | In-kind items and services | $25.18 | General |
| Category: NEPHROLOGY | ||||||
| 02/17/2022 | Bayer HealthCare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $19.86 | General |
| Category: Cardio-renal | ||||||
| 02/10/2022 | Horizon Therapeutics plc | KRYSTEXXA (Biological) | Food and Beverage | In-kind items and services | $27.75 | General |
| Category: KRYSTEXXA | ||||||
| 01/26/2022 | GlaxoSmithKline, LLC. | BENLYSTA (Biological) | Food and Beverage | In-kind items and services | $14.63 | General |
| Category: IMMUNOLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 7 | 454 | 1,451 | $449,297 | $144,021 |
| 2022 | 8 | 565 | 1,999 | $699,377 | $207,167 |
| 2021 | 9 | 755 | 2,409 | $832,688 | $263,692 |
| 2020 | 10 | 948 | 3,122 | $954,959 | $297,814 |
All Medicare Procedures & Services
34 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 153 | 714 | $184,362 | $66,091 | 35.8% |
| 90960 | Dialysis services, 4 or more physician visits per month (20 years or older) | Office | 2023 | 11 | 77 | $69,789 | $21,726 | 31.1% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 81 | 296 | $53,191 | $18,281 | 34.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 92 | 195 | $63,960 | $18,272 | 28.6% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 69 | 77 | $41,703 | $10,188 | 24.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 29 | 68 | $31,142 | $8,047 | 25.8% |
| 99497 | Advance care planning, first 30 minutes | Facility | 2023 | 19 | 24 | $5,150 | $1,415 | 27.5% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 193 | 970 | $250,464 | $76,343 | 30.5% |
| 90960 | Dialysis services, 4 or more physician visits per month (20 years or older) | Office | 2022 | 40 | 216 | $195,772 | $60,248 | 30.8% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 100 | 387 | $69,544 | $21,081 | 30.3% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 94 | 127 | $67,679 | $19,199 | 28.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 41 | 120 | $54,956 | $14,357 | 26.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 63 | 128 | $41,984 | $10,260 | 24.4% |
| 90961 | Dialysis services, 2-3 physician visits per month (20 years or older) | Office | 2022 | 11 | 15 | $11,253 | $3,543 | 31.5% |
| 99497 | Advance care planning, first 30 minutes | Facility | 2022 | 23 | 36 | $7,725 | $2,137 | 27.7% |
| 90960 | Dialysis services (4 or more physician visits per month), patient 20 years of age and older | Office | 2021 | 45 | 310 | $264,649 | $88,608 | 33.5% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 221 | 996 | $259,758 | $80,279 | 30.9% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 183 | 603 | $109,750 | $34,344 | 31.3% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 140 | 163 | $82,665 | $24,814 | 30.0% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 38 | 124 | $52,785 | $16,694 | 31.6% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 72 | 148 | $46,042 | $14,099 | 30.6% |
| 99497 | Advance care planning by the physician or other qualified health care professional, first 30 minutes | Facility | 2021 | 27 | 35 | $7,519 | $2,190 | 29.1% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2021 | 15 | 15 | $5,222 | $1,505 | 28.8% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Office | 2021 | 14 | 15 | $4,300 | $1,160 | 27.0% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 254 | 997 | $264,704 | $83,165 | 31.4% |
About Dr. Patrick Nef, M.D
Dr. Patrick Nef, M.D is a Nephrology healthcare provider based in Fort Worth, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 01/17/2008. The National Provider Identifier (NPI) number assigned to this provider is 1194901330.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Patrick Nef, M.D has received a total of $2,130 in payments from pharmaceutical and medical device companies, with $247.20 received in 2024. These payments were reported across 61 transactions from 19 companies. The most common payment nature is "Food and Beverage" ($2,127).
As a Medicare-enrolled provider, Nef has provided services to 2,722 Medicare beneficiaries, totaling 8,981 services with total Medicare billing of $912,694. Data is available for 4 years (2020–2023), covering 34 distinct procedure/service records.
Practice Information
- Specialty Nephrology
- Location Fort Worth, TX
- Active Since 01/17/2008
- Last Updated 10/28/2025
- Taxonomy Code 207RN0300X
- Entity Type Individual
- NPI Number 1194901330
Products in Payments
- KRYSTEXXA (Biological) $451.25
- ACTHAR (Biological) $244.50
- BENLYSTA (Biological) $242.05
- Velphoro (Drug) $225.00
- Auryxia (Drug) $136.34
- JYNARQUE (Drug) $136.26
- LOKELMA (Drug) $128.04
- Mavyret (Drug) $93.47
- Rayaldee (Drug) $80.27
- LUPKYNIS (Drug) $54.37
- Kerendia (Drug) $52.92
- JARDIANCE (Drug) $29.48
- GATTEX (Drug) $25.24
- RAYALDEE (Drug) $25.18
- General - Vascular Access (Device) $22.80
- (815) Thiola (Drug) $18.01
- Parsabiv (Biological) $16.06
- INJECTAFER (Drug) $15.91
- Cook Medical Accessories (Device) $13.36
- SAMSCA (Drug) $3.26
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Nephrology Doctors in Fort Worth
Sandeep Shori, Do, DO
Nephrology — Payments: $241,033
Michael Aragon, M.d, M.D
Nephrology — Payments: $138,471
Dr. Bernard Fischbach, M.d, M.D
Nephrology — Payments: $124,485
Renee Ellis, M.d, M.D
Nephrology — Payments: $46,269
Dr. Oladapo Afolabi, Md, MD
Nephrology — Payments: $18,976
Dr. Daniel Richey, D.o, D.O
Nephrology — Payments: $8,530